Developing YAP1 inhibitors or modulators as part of a treatment regimen for diabetes could potentially reduce the incidence or severity of DR, offering a substantial benefit over current therapies that mainly focus on the advanced stages of the disease. Here, YAP1 is linked to diabetes mellitus.